[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100595150":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":25,"locations":35,"responsibleParty":53,"collaborators":11,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":11,"maxAge":11,"enrollmentInfo":65,"targetDuration":11,"studyType":68,"phases":69,"briefSummary":71,"conditions":72,"keywords":11,"overallStatus":38,"whyStopped":11,"lastUpdateSubmitDate":74,"lastUpdatePostDateStruct":75,"startDateStruct":78,"completionDateStruct":80,"leadSponsor":82,"locationsCount":83},{"fullName":5,"class":6},"University Hospital, Montpellier","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"1","EXPERIMENTAL",null,[13],"Drug: hCG",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":11},"DRUG","hCG","Subcutaneous injection of 250 µg of recombinant hCG (Ovitrelle®)",[9],[21],{"name":22,"affiliation":23,"role":24},"Noémie RANISAVLJEVIC, Investigator Coordinator","CHU de Montpellier","PRINCIPAL_INVESTIGATOR",[26,31],{"name":27,"role":28,"phone":29,"phoneExt":11,"email":30},"Noémie RANISAVLJEVIC, Senior Lecturer - Hospital Pra","CONTACT","04 67 33 64 81","n-ranisavljevic@chu-montpellier.fr",{"name":32,"role":28,"phone":33,"phoneExt":11,"email":34},"Anne CADENE, Project manager","04.67.33.08.14","a-cadene@chu-montpellier.fr",[36],{"facility":37,"status":38,"city":39,"state":11,"zip":40,"country":41,"countryCode":42,"cosmosGeoPoint":43,"geoPoint":48,"contacts":49},"Hôpital Arnaud de Villeneuve","RECRUITING","Montpellier","34000","France","FR",{"type":44,"coordinates":45},"Point",[46,47],3.87635,43.61093,{"lat":47,"lon":46},[50],{"name":51,"role":28,"phone":29,"phoneExt":52,"email":30},"Noémie RANISAVLJEVIC","+33",{"type":54,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100595150","early-luteal-phase-progesterone-kinetics-after-hcg-induced-ovulation-in-modified-natural-cycle-100595150",false,"NCT07028710","Early Luteal Phase Progesterone Kinetics After hCG-Induced Ovulation in Modified Natural Cycle","Evolution of Luteal Progesteronemia in a Modified Natural Cycle (Ovulation Triggered by hCG): Pilot Study","CineP4","Inclusion Criteria:\n\n* At least 1 follicle of 14 mm or more\n* Endometrium of 6 mm or more\n* Plasma luteinizing hormone (LH) less than 2 times basal level (measured at the beginning of the cycle between D1 and D4) and progesteronemia less than 1.5 ng\u002FmL\n* For whom ovulation induction with recombinant hCG (Ovitrelle) is then proposed (standard care).\n\nExclusion Criteria:\n\n* Patient whose venous capital contraindicates repeated blood sampling over a short period of time over a short period.\n* Patient treated with exogenous natural progesterone (vaginal or injectable) which may interfere or synthetic progesterone, which may interfere with endogenous progesterone secretion.\n* Patient who has not given written consent to participate in the study.\n* Patient not fluent in French.\n* Patient under guardianship, curators or without social security coverage.\n* Patient participating in another study with an ongoing exclusion period or other interventional research with no ongoing exclusion period involves the use of a drug or procedure capable of altering progesterone levels .",true,"FEMALE",{"count":66,"type":67},40,"ESTIMATED","INTERVENTIONAL",[70],"NA","This pilot study evaluates how progesterone levels change after hCG-triggered ovulation in modified natural cycles. Forty women preparing for frozen embryo transfer will have blood tests over 6 days to monitor hormone levels. The goal is to understand whether hCG affects the timing of the luteal phase and embryo implantation.",[73],"Luteal Phase Insufficiency","2026-06-17",{"date":76,"type":77},"2026-06-22","ACTUAL",{"date":79,"type":77},"2026-01-12",{"date":81,"type":67},"2030-06-15",{"name":5,"class":6},1]